India Administers 80 Lakh HPV Vaccine Doses, Marking Major Milestone in Cervical Cancer Prevention

Science & Technology / Public Health · 12 September 2026 · Based on PIB (original report)

Worth reading — 1 past UPSC question on this theme (Prelims GS-1 2021).

2-minute summary

India's Ministry of Health and Family Welfare has achieved a significant milestone by administering 80 lakh (8 million) doses of the Human Papillomavirus (HPV) vaccine. Cervical cancer is the second most common cancer among women in India, which accounts for nearly one-fifth of the global cervical cancer burden. To combat this, India has integrated the HPV vaccine into its public health frameworks, targeting adolescent girls aged 9-14 years. This milestone reflects India's growing capacity in preventive healthcare, bolstered by the development of CERVAVEC, India's first indigenous quadrivalent HPV vaccine developed by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT). The scale-up of this vaccination drive is a crucial step towards the World Health Organization's (WHO) global target of eliminating cervical cancer by 2030, highlighting India's commitment to improving women's health outcomes and reducing the national disease burden through accessible, cost-effective immunization.

Why it's in the news

The Ministry of Health and Family Welfare announced that India has successfully administered 80 lakh doses of the Human Papillomavirus (HPV) vaccine, marking a major milestone in the country's cervical cancer prevention and public health efforts.

Facts to remember

• India's Ministry of Health and Family Welfare achieved a milestone by administering 80 lakh doses of the Human Papillomavirus (HPV) vaccine.
• Cervical cancer is the second most common cancer among women in India, which accounts for nearly one-fifth of the global cervical cancer burden.
• CERVAVEC is India's first indigenous quadrivalent HPV vaccine developed by the Serum Institute of India in collaboration with the Department of Biotechnology.
• CERVAVEC targets HPV types 6, 11, 16, and 18.
• The WHO global strategy outlines the '90-70-90' targets by 2030, including vaccinating 90% of girls with the HPV vaccine by age 15.

Background and context

Cervical cancer is primarily caused by persistent infection with high-risk types of Human Papillomavirus (HPV). In India, it is the second most frequent cancer among women aged 15 to 44 years, causing over 75,000 deaths annually. Recognizing this critical public health challenge, the National Technical Advisory Group on Immunization (NTAGI) recommended the introduction of the HPV vaccine in the Universal Immunization Programme (UIP). A major breakthrough occurred with the launch of CERVAVEC, India's first indigenous quadrivalent HPV vaccine (targeting HPV types 6, 11, 16, and 18), developed by the Serum Institute of India under the Department of Biotechnology's support. This indigenous development significantly lowered costs compared to imported vaccines, enabling the government to plan and execute large-scale immunization campaigns targeting adolescent girls aged 9 to 14 years, which is the most effective window for HPV vaccination before exposure to the virus.

Constitutional provisions

• Article 21 — Right to Life and Personal Liberty, which has been judicially interpreted by the Supreme Court to include the right to health and affordable healthcare.
• Article 47 — Directive Principle of State Policy directing the State to regard the raising of the level of nutrition, standard of living, and the improvement of public health as among its primary duties.

Committees and reports

• National Technical Advisory Group on Immunization (NTAGI) Recommendation on HPV Vaccine — Recommended the introduction of the HPV vaccine into the Universal Immunization Programme (UIP) targeting adolescent girls aged 9-14 years.
• WHO Global Strategy to Accelerate the Elimination of Cervical Cancer — Outlined the '90-70-90' targets by 2030, including vaccinating 90% of girls with the HPV vaccine by age 15.

Government schemes

• Universal Immunization Programme (UIP) — The national immunization framework under which the HPV vaccine is being scaled up to target adolescent girls.
• National Health Mission (NHM) — Supports the strengthening of primary health infrastructure, screening for non-communicable diseases (including cervical cancer), and vaccine delivery logistics.

International organisations

• World Health Organization (WHO) — Leads the global cervical cancer elimination initiative and provides guidelines on HPV vaccination schedules.
• Gavi, the Vaccine Alliance — Works globally to improve access to new and underused vaccines for children and adolescents in developing countries.

Previous UPSC questions on this theme

• Prelims GS-1 2021 — With reference to recent developments regarding 'Recombinant Vector Vaccines', consider the following statements : 1. Genetic engineering is applied in the development of these vaccines. 2. Bacteria and viruses are used as vectors. Which of the statements given above is/are correct? (a) 1 only (b) 2 only (c) Both 1 and 2 (d) Neither 1 nor 2

Mains practice: Cervical cancer remains a significant public health challenge for women in India. Discuss the role of indigenous vaccine development and the Universal Immunization Programme in achieving the goal of cervical cancer elimination.

Cervical cancer is the second most common cancer among Indian women, accounting for nearly 18% of the global burden. The administration of 80 lakh HPV vaccine doses marks a critical milestone in India's preventive healthcare strategy, aligning with the WHO's global target to eliminate cervical cancer by 2030.

• **Role of Indigenous Vaccine Development**: The development of CERVAVEC, India’s first indigenous quadrivalent HPV vaccine by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT), has been a game-changer. It addresses the critical barrier of affordability, reducing costs significantly compared to expensive imported alternatives like Gardasil. This indigenization supports the 'Atmanirbhar Bharat' vision and ensures a sustainable domestic supply chain.

• **Integration into the Universal Immunization Programme (UIP)**: By incorporating the HPV vaccine into the UIP, the government targets adolescent girls aged 9-14 years. This school-based and community-linked delivery model ensures high coverage, leveraging existing immunization infrastructure (like the U-WIN portal) to track and manage doses.

• **Socio-Economic and Structural Challenges**: Despite progress, challenges persist. These include widespread vaccine hesitancy driven by misinformation, lack of awareness about cervical cancer, and regional disparities in healthcare infrastructure. Additionally, screening coverage for adult women remains low (less than 10%), which is a critical gap in secondary prevention.

• **Way Forward**: To achieve elimination, India must adopt a multi-pronged approach: enhancing public awareness campaigns to dispel myths, strengthening school-based immunization drives, and integrating HPV screening (DNA-based testing) into primary health centers under Ayushman Bharat.

In conclusion, India's milestone of 80 lakh doses demonstrates the power of combining indigenous scientific innovation with robust public health frameworks. Sustained political will and community engagement will be vital to transition from control to complete elimination of cervical cancer.

Prelims practice questions

Q1. With reference to the Human Papillomavirus (HPV) and cervical cancer, consider the following statements: 1. HPV is a DNA virus primarily transmitted through sexual contact. 2. CERVAVEC is India's first indigenous quadrivalent HPV vaccine developed by Bharat Biotech. 3. The World Health Organization (WHO) aims to eliminate cervical cancer globally by 2030 through its 90-70-90 targets. Which of the statements given above are correct?

1. 1 and 2 only
2. 1 and 3 only
3. 2 and 3 only
4. 1, 2 and 3

Answer: B. Statement 1 is correct. Statement 2 is incorrect because CERVAVEC was developed by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT), not Bharat Biotech. Statement 3 is correct; the WHO's 90-70-90 targets by 2030 include 90% of girls fully vaccinated with HPV vaccine by age 15, 70% of women screened with a high-performance test by 35 and 45, and 90% of women identified with cervical disease receiving treatment.

Q2. Which of the following statements best describes a 'quadrivalent' vaccine, such as the indigenous CERVAVEC vaccine?

1. A vaccine designed to stimulate both active and passive immunity simultaneously.
2. A vaccine that requires four booster doses over a span of five years.
3. A vaccine that targets four different strains or types of a pathogen to provide broader protection.
4. A vaccine that is administered only to individuals in the age group of 9 to 14 years.

Answer: C. A quadrivalent vaccine works by stimulating an immune response against four different antigens, such as four different strains of a virus. CERVAVEC is a quadrivalent vaccine targeting HPV types 6, 11, 16, and 18.

Q3. Under the Directive Principles of State Policy (DPSP) of the Indian Constitution, which Article explicitly directs the State to regard the raising of the level of nutrition and the standard of living of its people and the improvement of public health as among its primary duties?

1. Article 39
2. Article 43
3. Article 47
4. Article 45

Answer: C. Article 47 of the Constitution of India states that the State shall regard the raising of the level of nutrition and the standard of living of its people and the improvement of public health as among its primary duties.

Revision flashcards

• What is CERVAVEC and who developed it? CERVAVEC is India's first indigenous quadrivalent Human Papillomavirus (qHPV) vaccine, developed by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT).
• Which HPV strains are targeted by quadrivalent HPV vaccines like CERVAVEC? HPV types 6, 11, 16, and 18. Types 16 and 18 cause about 70% of cervical cancers, while 6 and 11 cause genital warts.
• What is the target age group for the HPV vaccination drive under India's Universal Immunization Programme? Adolescent girls aged 9 to 14 years, as the vaccine is most effective when administered before exposure to the virus.
• What are the WHO's '90-70-90' targets for cervical cancer elimination by 2030? 90% of girls fully vaccinated with HPV vaccine by age 15; 70% of women screened using a high-performance test by age 35 and 45; 90% of women with pre-cancer/cancer treated.
• Which constitutional article guarantees the right to health as an extension of the Right to Life? Article 21 of the Constitution of India, as interpreted by the Supreme Court in various landmark judgments.